Pfizer appoints David M. Denton Chief Financial Officer
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced that David M. Denton will join the company as Chief Financial Officer (CFO) and Executive Vice President effective May 2, 2022 Mr. Denton will be a member of Pfizer’s management team and report to Chairman and Chief Executive Officer, Albert Bourla. Prior to joining Pfizer, he worked for Lowe’s Companies, Inc., where he served as Chief Financial Officer and Executive Vice President. Mr. Denton succeeds Frank D’Amelio, Chief Financial Officer and Executive Vice President, who recently announced his intention to leave Pfizer after a distinguished 15-year career. Mr. D’Amelio has agreed to remain in place for a transition period.
Mr. Denton has over 25 years of financial and operational expertise, including more than 20 years in the healthcare industry. As a result, he brings to Pfizer a unique perspective on the role of payers, patient needs, and the rapidly changing healthcare landscape.
At Pfizer, Mr. Denton will be a key partner to the company’s CEO and management team while overseeing all aspects of the company’s financial management. He will be responsible for all financial functions of the business, including audit, treasury, tax, insurance, operations planning and analysis (OP&A), management control, as well as finance. and business analysis.
“The continued financial strength of our company is critical to Pfizer’s ability to achieve our goal and create long-term value for all of our stakeholders,” said Albert Bourla, president and chief executive officer of Pfizer. “Dave brings with him deep financial experience, a track record of accomplishments and a true understanding of today’s healthcare system. For these reasons, he is the ideal leader to lead our talented finance organization and provide an overall strategic finance vision that will contribute to Pfizer’s future growth and success.
Bourla continued, “My sincere thanks to Frank D’Amelio for his many lasting contributions to Pfizer, including mentoring so many of today’s outstanding Pfizer leaders and improving the lives of so many patients around the world.
“We live in a time of unprecedented scientific advances and Pfizer is an unprecedented company in its ambition to make a difference in the lives of patients. For me, there could be no greater professional opportunity than to take advantage of all my years of finance and business experience to play a part in achieving this aspiration, working alongside a high-performing team that was built for growth and improved returns for shareholders,” said said David Denton.
Prior to joining Lowe’s in 2018, Mr. Denton served as Executive Vice President and Chief Financial Officer of CVS Health, where he was responsible for all aspects of their financial planning and management. He played a key role in CVS’ transformation journey from a retail pharmacy to the healthcare solutions company it is today and led the full integration of Caremark into CVS. In December 2017, Mr. Denton played a central role in the acquisition of Aetna by CVS, structuring and negotiating the terms and financing of the transaction.
Prior to becoming Chief Financial Officer at CVS, Mr. Denton held several leadership positions including Senior Vice President and Controller/Chief Accounting Officer. Prior to CVS, he worked for the management consulting firm Deloitte Touche Tohmatsu.
He earned a Bachelor of Business Administration from Kansas State University, USA and an MBA from the Babcock Graduate School of Management at Wake Forest University, USA. He serves on the Board of Tapestry, Inc.
About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring people therapies that dramatically extend and improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of healthcare products, including innovative medicines and vaccines. Every day, Pfizer colleagues work in developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. In line with our responsibility as one of the world’s leading innovative biopharmaceutical companies, we work with healthcare providers, governments and local communities to support and expand access to reliable and affordable healthcare in the whole world. For over 170 years, we’ve worked to make a difference for everyone who counts on us. We regularly post information that may be important to investors on our website at www.Pfizer.com. Also, to learn more, visit us at www.Pfizer.com and follow us on Twitter at @Pfizer and @PfizerNewsLinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
Notice of Disclosure:The information in this release is as of April 11, 2022. The Company undertakes no obligation to update any forward-looking statements contained in this release as a result of new information or future events or developments.
This release contains forward-looking information about, among other things, the value creation and growth potential of the Company that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied. by these statements. Risks and uncertainties include, among others, uncertainties inherent in research and development; uncertainties inherent in business and financial planning, including, without limitation, risks relating to Pfizer’s business and prospects, adverse developments in Pfizer’s markets or adverse developments in U.S. or global capital markets, credit markets, the regulatory environment or economies in general; the impact of COVID-19 on our business, operations and financial results; and competitive developments.
A more detailed description of the risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and its subsequent reports on Form 10-Q, including in sections herein entitled “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, and in its subsequent reports on Form 8-K, all of which are filed with the United States Securities and Exchange Commission and available at www.sec.gov and www. pfizer.com.
+1 (212) 733-1226
+1 (212) 733-4848
Source: Pfizer Inc.